If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]
Lyon (France), and Cambridge, MA (US) on April 06, 2022 – ERYTECH Pharma (Euronext: ERYP; Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drugs in red blood cells (RBCs) , today announces the publication in the British Journal of Haematology of the results of the Phase 2 clinical study, conducted by NOPHO, in the treatment of patients with hypersensitive ALL with eryaspase.